Aflibercept (fusion protein targeting VEGF-A, VEGF-B isoforms, and PLGF) [3,4], brolucizumab (a humanized single-chain antibody fragment against VEGF-A) [5], and faricimab (bispecific mAb targeting VGEF-A and Ang-2) [6] are marketed for age-related macular degeneration (AMD) and diabetic macular edema (DME). This evidence concerns the gene VEGFA and diabetic macular edema.